Table 2.
Demographic and Clinical Characteristics
| Characteristic | EINSTEIN DVT | EINSTEIN PE | EINSTEIN Pooled | |||
|---|---|---|---|---|---|---|
| Rivaroxaban | Heparin/ VKA | Rivaroxaban | Heparin/ VKA | Rivaroxaban | Heparin/ VKA | |
| (N = 1,731) | (N = 1,718) | (N = 2,419) | (N = 2,413) | (N = 4,150) | (N = 4,131) | |
| Male sex | 993 (57.4) | 967 (56.3) | 1309 (54.1) | 1247 (51.7) | 2302 (55.5) | 2214 (53.6) |
| Age (yr) | 55.8 ± 16.4 | 56.4 ± 16.3 | 57.9 ± 17.3 | 57.5 ± 17.2 | 57.0 ± 17.0 | 57.0 ± 16.8 |
| Race (white) | 1,327 (76.7) | 1,319 (76.8) | 1,585 (65.5) | 1,587 (65.8) | 2,912 (70.2) | 2,906 (70.3) |
| Recent surgery or trauma | 338 (19.5) | 335 (19.5) | 415 (17.2) | 398 (16.5) | 753 (18.1) | 733 (17.7) |
| Previous VTE | 336 (19.4) | 330 (19.2) | 455 (18.8) | 489 (20.3) | 791 (19.1) | 819 (19.8) |
| Active cancer | 118 (6.8) | 89 (5.2) | 114 (4.7) | 109 (4.5) | 232 (5.6) | 198 (4.8) |
| Immobilization | 265 (15.3) | 260 (15.1) | 384 (15.9) | 380 (15.7) | 649 (15.6) | 640 (15.5) |
| Known thrombophilic condition | 107 (6.2) | 116 (6.8) | 138 (5.7) | 121 (5.0) | 245 (5.9) | 237 (5.7) |
| Unprovoked VTE | 1,055 (60.9) | 1,083 (63.0) | 1,566 (64.7) | 1,551 (64.3) | 2,621 (63.1) | 2,634 (63.8) |
| Duration of treatment (days)a | 193.6 ± 89.3 | 187.5 ± 92.5 | 216.3 ± 98.7 | 214.3 ± 98.9 | 207.6 ± 95.9 | 203.8 ± 97.4 |
Data are shown as n (%) or mean ± SD.
a
Duration of actual study treatment after randomization until end of treatment (safety population).
DVT = deep venous thrombosis; PE = pulmonary embolism; VKA = vitamin K antagonist; VTE = venous thromboembolism.